TOKYO -- As Takeda Pharmaceutical readies new drugs expected to generate billions of dollars in revenue, recent staff and R&D cutbacks have raised questions about the future of its pipeline.
Pharmaceuticals
Takeda job cuts cloud R&D outlook as drugmaker touts pipeline
Company needs new blockbusters as big seller heads toward patent cliff, analysts say
CEO Christophe Weber is leading Japan's biggest drug company through a shakeup of its R&D operations. (Photo by Wataru Ito)
Read Next
Latest on Pharmaceuticals
